For example, in oncogenic BRAF-driven melanomas, BRN2 expression is elevated through hyperactivated MAPK signaling, which transcriptionally represses the cGMP-specific phosphodiesterase PDE5A (106, 107). The gene discussed is BRAF; the disease is melanoma.